Multiple Myeloma with a Special Focus on Precision Medicine
Multiple myeloma (MM) is the most common hematological malignancy. Risk stratification was relevantly refined in recent years regarding, among others, the revised international staging system (R-ISS) and expanded knowledge about the influence of cytogenetic abnormalities. The introduction of the &qu...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2020-12-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/hbT.OH.2020.06.023 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846126485759328256 |
|---|---|
| author | Adrian Schmidt |
| author_facet | Adrian Schmidt |
| author_sort | Adrian Schmidt |
| collection | DOAJ |
| description | Multiple myeloma (MM) is the most common hematological malignancy. Risk stratification was relevantly refined in recent years regarding, among others, the revised international staging system (R-ISS) and expanded knowledge about the influence of cytogenetic abnormalities. The introduction of the "SLiM"-criteria led to the paradigm shift of early treatment of high-risk smoldering myeloma. Finally, the huge progress in therapeutic modalities over the last two decades makes the therapy of multiple myeloma more satisfying for patients and physicians, yet much more challenging. As further promising innovations are introduced in clinical practice, multiple myeloma is increasingly perceived as a chronic disease, with some patients achieving long-term-remissions. Here we describe the progress made in recent years, presenting the most important drugs, therapeutic concepts, and new developments in the field of multiple myeloma. |
| format | Article |
| id | doaj-art-2e928cf523844e3fb7578f105b805cff |
| institution | Kabale University |
| issn | 2673-2106 |
| language | English |
| publishDate | 2020-12-01 |
| publisher | THE HEALTHBOOK COMPANY LTD. |
| record_format | Article |
| series | healthbook TIMES. Oncology Hematology |
| spelling | doaj-art-2e928cf523844e3fb7578f105b805cff2024-12-12T17:11:25ZengTHE HEALTHBOOK COMPANY LTD.healthbook TIMES. Oncology Hematology2673-21062020-12-0164Multiple Myeloma with a Special Focus on Precision MedicineAdrian SchmidtMultiple myeloma (MM) is the most common hematological malignancy. Risk stratification was relevantly refined in recent years regarding, among others, the revised international staging system (R-ISS) and expanded knowledge about the influence of cytogenetic abnormalities. The introduction of the "SLiM"-criteria led to the paradigm shift of early treatment of high-risk smoldering myeloma. Finally, the huge progress in therapeutic modalities over the last two decades makes the therapy of multiple myeloma more satisfying for patients and physicians, yet much more challenging. As further promising innovations are introduced in clinical practice, multiple myeloma is increasingly perceived as a chronic disease, with some patients achieving long-term-remissions. Here we describe the progress made in recent years, presenting the most important drugs, therapeutic concepts, and new developments in the field of multiple myeloma.https://doi.org/10.36000/hbT.OH.2020.06.023 |
| spellingShingle | Adrian Schmidt Multiple Myeloma with a Special Focus on Precision Medicine healthbook TIMES. Oncology Hematology |
| title | Multiple Myeloma with a Special Focus on Precision Medicine |
| title_full | Multiple Myeloma with a Special Focus on Precision Medicine |
| title_fullStr | Multiple Myeloma with a Special Focus on Precision Medicine |
| title_full_unstemmed | Multiple Myeloma with a Special Focus on Precision Medicine |
| title_short | Multiple Myeloma with a Special Focus on Precision Medicine |
| title_sort | multiple myeloma with a special focus on precision medicine |
| url | https://doi.org/10.36000/hbT.OH.2020.06.023 |
| work_keys_str_mv | AT adrianschmidt multiplemyelomawithaspecialfocusonprecisionmedicine |